Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Dicernatm to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020


Dicernatm Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2019 financial results after market close on Thursday, Feb. 27, 2020.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available on the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website.

The call can be accessed by dialing (855) 453-3834 or (484) 756-4306 (international) and referencing conference ID 3259673 prior to the start of the call. After the conference call, a replay will be available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and refer to conference ID 3259673.

About Dicernatm Pharmaceuticals, Inc.

Dicernatm Pharmaceuticals, Inc., is a biopharmaceutical company using ribonucleic acid interference (RNAi) to develop medicines that silence genes that cause disease. The Company's proprietary GalXCtm technology is being applied to develop potent, selective and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit www.dicerna.com.

Dicernatm and GalXCtm are trademarks of Dicerna Pharmaceuticals, Inc.


These press releases may also interest you

at 08:07
Lindus Health Debuts "All-in-One Diagnostics CRO" Solution for Diagnostic Clinical Trials
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has released a comprehensive contract research organization (CRO) offering tailor-made for sponsors looking to bring diagnostic products...

at 08:05
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...

at 08:05
Revvity to Present at BofA Securities 2024 Health Care Conference
Revvity, Inc. will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its...

at 08:05
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the...

at 08:05
Microbion Receives Award at Advanced Wound Care Summit USA's Innovation Showcase
Microbion Corporation today announced that the company won the Advanced Wound Care Summit's Innovation Showcase award. The Innovation Showcase was designed to give presenters, who were picked by a selection committee, an opportunity to demonstrate...

More news about Health...


News published on and distributed by: